Brief Description
The purpose of this study is to assess the efficacy and safety of twice weekly pegcetacoplan compared to placebo in patients with C3G or IC-MPGN, on the basis of a reduction in urinary protein levels.
Estimated Enrollment
Approximately 90
Estimated End Date
March 2025
Trial is for people with
Confirmed C3G or IC-MPGN, with or without prior renal transplantation. In addition, participants must: • Be at least 12 years old ...
Study Goal
The VALIANT study will assess whether pegcetacoplan, an investigational targeted C3 inhibitor, has an effect on the damage to kidney ...
What is involved for the patient?
After completing the screening period to confirm that the patient is able to participate in the study, individuals will be randomly ...
About the drug or intervention
Pegcetacoplan is an investigational, targeted C3 inhibitor. It is administered via a needle, under the skin (subcutaneous), twice ...